Over the summer I was lucky enough to be invited to a 60th birthday at which the after-dinner entertainment was a private performance by one of the UK’s leading male pop stars. More eye-popping than the actual show, though, was how incredible said star looked. He was a mere shadow of his former self, prancing around the stage in a silver catsuit. His secret? Semaglutide, or Ozempic as it is branded, a new diet drug that everybody – but everybody, darling, including one of the world’s most famous supermodels – is apparently taking.
Originally developed to treat type 2 diabetes, it is used off-label (for a purpose other than that for which it was licensed) in both the US and the UK to treat obesity. In research conducted by its billionaire manufacturer, the Danish-based pharmaceutical company Novo Nordisk, patients lost an average of 17 per cent of their overall body weight over 68 weeks. This compares with five to nine per cent for ‘oldschool’ anti-obesity drugs such as…